Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders
QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing
09-Sep-2022 -
Qli5 Therapeutics GmbH (QLi5), a German-Korean joint venture developing a new class of proteasome inhibitors, has closed a EUR 10 million series A financing round with an international consortium of investors including SV Investment (Korea), KHAN Technology Transfer Fund I (Germany), Atinum ...
autoimmune diseases
cancer
inflammation
+3